相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia
Eduardo Olavarria et al.
BLOOD (2007)
Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone
Jeffrey S. Miller et al.
BLOOD (2007)
Graft-versus-leukemia effects associated with detectable Wilms tumor-1-specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia
Katayoun Rezvani et al.
BLOOD (2007)
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders
ChunKang Chang et al.
BLOOD (2007)
Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant
D. Vicente et al.
BONE MARROW TRANSPLANTATION (2007)
Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission
Martin S. Tallman et al.
BLOOD (2007)
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia
Alida Dominietto et al.
BLOOD (2007)
Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant alemtuzumab
Emma P. Das-Gupta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning
A. P. Grigg et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
Jan J. Cornelissen et al.
BLOOD (2007)
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Jeffrey E. Lancet et al.
BLOOD (2007)
Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: A comparison with an every 6-hour dosing schedule
Timothy Madden et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Unrelated stem cell transplantation after a reduced intensity conditioning regimen containing high-dose thymoglobulin leads to controllable graft-versus-host disease
J. F. Lacerda et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches
Jochen Greiner et al.
BLOOD (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: A British Society of Blood and Marrow Transplantation registry study
Andrew D. Chantry et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Steven Knapper et al.
BLOOD (2006)
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years:: Results from AMLSG trial AML HD98-B
Stefan Froehling et al.
BLOOD (2006)
Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block
Peggy Kirstetter et al.
NATURE IMMUNOLOGY (2006)
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9
Andrei V. Krivtsov et al.
NATURE (2006)
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2006)
Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia:: graft-versus-tumor effect and long-term remission
H de Lavallade et al.
BONE MARROW TRANSPLANTATION (2006)
Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia:: a retrospective analysis from the Center for International Blood and Marrow Transplant Research
HM Lazarus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
U Hegenbart et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Therapeutic and diagnostic applications of minor histocompatibility antigen HA-1 and HA-2 disparities in allogeneic hematopoietic stem cell transplantation: A survey of different populations
S Di Terlizzi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
EBMT activity survey 2004 and changes in disease indication over the past 15 years
A. Gratwohl et al.
BONE MARROW TRANSPLANTATION (2006)
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia
S Tauro et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
mTOR regulates cell survival after etoposide treatment in primary AML cells
Q Xu et al.
BLOOD (2005)
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics:: interaction with other gene mutations
K Döhner et al.
BLOOD (2005)
Treatment of older patients with AML
T Büchner et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells
SA Xue et al.
BLOOD (2005)
Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: An intent-to-treat long-term analysis of the BGMT experience
E Jourdan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gene expression profiling in acute myeloid leukemia
L Bullinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Genetics of myeloid malignancies:: Pathogenetic and clinical implications
S Fröhling et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome
C Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome
K van Besien et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia:: a donor vs no donor comparison
M Mohty et al.
LEUKEMIA (2005)
Prognostically useful gene-expression profiles in acute myeloid leukemia
PJM Valk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors
D Blaise et al.
BLOOD (2004)
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning
AYL Ho et al.
BLOOD (2004)
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
M de Lima et al.
BLOOD (2004)
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
M de Lima et al.
BLOOD (2004)
Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents:: The histocompatibility and alternate stem cell source working committee of the International Bone Marrow Transplant Registry
M Eapen et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: Impact of cytogenetic characteristics on transplantation outcome
HC Fung et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2003)
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years
R Wong et al.
BLOOD (2003)
Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease
F Lo-Coco et al.
LEUKEMIA (2003)
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning
JN Barker et al.
BLOOD (2003)
Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting
DC Taussig et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CRI): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial
S Suciu et al.
BLOOD (2003)
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells
M Bornhäuser et al.
BLOOD (2003)
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen
M Mohty et al.
BLOOD (2003)
Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation
BR Dey et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2003)
Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia
H Bertz et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia
H Ogawa et al.
BLOOD (2003)
Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen
M Mohty et al.
LEUKEMIA (2003)
Preferential induction of apoptosis for primary human leukemic stem cells
ML Guzman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Nonmyeloablative transplantation with or without alemtuzumab:: comparison between 2 prospective studies in patients with lymphoproliferative disorders
JA Pérez-Simón et al.
BLOOD (2002)
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation
DI Marks et al.
BLOOD (2002)
CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia
C Scheibenbogen et al.
BLOOD (2002)
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome
HJ Deeg et al.
BLOOD (2002)
The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial
AK Burnett et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen
R Chakraverty et al.
BLOOD (2002)
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia:: long-term follow-up of 4 randomized studies
G Socié et al.
BLOOD (2001)
Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells
ML Guzman et al.
BLOOD (2001)
Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg™ CMA-676)
MC Petti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back
R Nakamura et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial
D Grimwade et al.
BLOOD (2001)
Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission
D Blaise et al.
BLOOD (2001)
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
WI Bensinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation
PD Kottaridis et al.
CYTOTHERAPY (2001)
Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience
J Sierra et al.
BONE MARROW TRANSPLANTATION (2000)
分享论文
